Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Primary Hip Prosthesis System
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- TIPMED Medical Device Manufacturing Ltd. Co.
- Trial code
- NCT07651735
- Record updated
- 16 June 2026
- Original description
This is a multicenter, prospective, observational, post-market clinical follow-up (PMCF) study designed to evaluate the safety and clinical performance of the Tipmed™ Primary Hip Prosthesis System in adult subjects undergoing primary hip arthroplasty. The study aims to gather real-world clinical evidence on the 24-month post-operative safety profile, potential complications, and functional outcomes of the device during routine clinical practice.Read full original descriptionShow less
A Multicenter, Prospective, Observational, Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Primary Hip Prosthesis System
This is a multicenter, prospective, observational, post-market clinical follow-up (PMCF) study designed to evaluate the safety and clinical performance of the Tipmed™ Primary Hip Prosthesis System in adult subjects undergoing primary hip arthroplasty. The study aims to gather real-world clinical evidence on the 24-month post-operative safety profile, potential complications, and functional outcomes of the device during routine clinical practice.
Inclusion: Individuals aged 18 years and older,; Male or female participants,; Subjects who have undergone Primary Hip Arthroplasty (either total or partial) for any indication,; Subjects in whose surgical procedure the Tipmed™ Primary Hip Prosthesis System components were utilized; Subjects who are not legally restricted (e.g., military personnel, convicts, or individuals under legal guardianship); Subjects who have voluntarily signed the written Informed Consent Form (ICF).
Exclusion: Subjects currently participating in any other interventional clinical trial.